BeiGene, Ltd. (BGNE)

167,92 +0,53 (+0,32 %) À la clôture : 04:00PM EDT

BeiGene, Ltd.

94 Solaris Avenue
Camana Bay KY1-1108
Cayman Islands
345-949-4123
https://www.beigene.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 10 000

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Mr. John V. Oyler	Co-Founder, Executive Chairman & CEO	2,43M	S.O.	1968
Dr. Xiaobin Wu Ph.D.	President & COO	1,7M	S.O.	1962
Dr. Xiaodong Wang Ph.D.	Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder	4,42M	S.O.	1963
Ms. Julia Wang	CFO & Principal Financial Officer	1,07M	S.O.	1971
Mr. Chan Lee	General Counsel & Senior VP	1,01M	S.O.	1968
Mr. Wang Lai Ph.D.	Global Head of R&D	1,12M	S.O.	1977
Mr. Titus B. Ball	VP & Chief Accounting Officer	S.O.	S.O.	1973
Ms. Liza Heapes	Head of Investor Relations	S.O.	S.O.	S.O.
Mr. Yang Ji	Chief Compliance Officer	S.O.	S.O.	S.O.
Dr. Yan Qi	Senior VP & Head of Public Affairs - Greater China	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

BeiGene Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.

Gouvernance d’entreprise

L’ISS Governance QualityScore de BeiGene, Ltd. en date du 1 mai 2024 est 8. Les scores principaux sont Audit : 9; Société : 5; Droits des actionnaires : 6; Compensation : 10.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.